Skip to main content

Table 1 Clinicopathological characteristics

From: The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

  No. of patients (70) %
Age, median (range, year) 70 (44–85)  
Gender
Male 48 69
Female 22 31
Histology
Adenocarcinoma 54 77
Squamous 15 22
NOS 1 1
Stage
IIIB 3 4
IV 67 96
ECOG PS
0 25 36
1 39 56
2 6 8
Smoking habits
Never smoker 9 13
Former smoker 35 50
Smoker 26 37
Prior lines of therapy Median 2 (range 1–6)  
1 28 40
2 20 29
3 13 19
≥ 4 9 12
CEA (ng/ml) baseline
Median (range) 6.6 (0.80–2615)  
Normal (< 5) 30 43
Elevated (≥ 5) 40 57
CYFRA 21-1 (ng/ml) baseline
Median (range) 5.0 (0.2–126.4)  
Normal (< 3.3) 25 36
Elevated (≥ 3.3) 45 64
NSE (ng/ml) baseline
Median (range) 7.5 (3.1–46.8)  
Normal (< 3.3) 56 80
Elevated (≥ 3.3) 14 20
  1. NOS, not otherwise specified; ECOG, Eastern cooperative oncology group; PS, performance status; CEA, carcinoembryonic antigen; CYFRA21-1, cytokeratin fragment 19; NSE, neuron-specific enolase